2 results
Approved WMOCompleted
To assess the anti-tumor activity of LGX818/MEK162 in combination with third targeted agents after progression on LGX818/MEK162 combination therapy.
Approved WMOCompleted
To assess uptake of 18F-PD-L1 and 89Zr- nivolumab in tumor lesions.